title: Lack of relationship between 17-hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome.
abstract: OBJECTIVE
  To determine whether hyperinsulinism affects cytochrome P450c17 alpha activity by investigating the correlation between 17-hydroxyprogesterone (17-OHP) hyper-responsiveness to the gonadotropin-releasing hormone (GnRH) agonist, buserelin, and the insulin response to oral glucose in polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Ultrasound, clinical and hormonal parameters were used to define PCOS in this prospective clinical study. We investigated the correlation between the 17-OHP response to buserelin testing and the insulin response to oral glucose in PCOS.
  
  
  METHODS
  Twenty-eight women with PCOS and eighteen normal women were included in the study. 17-OHP response to buserelin, and insulin and C-peptide responses to oral glucose were measured.
  
  
  RESULTS
  Twenty-five women with PCOS had an increased 17-OHP response. The PCOS patients showed significantly higher mean post-glucose load insulin and C-peptide levels than controls (P < 0.05). No significant correlations were found between basal 17-OHP and fasting insulin or fasting C-peptide, between peak 17-OHP and fasting insulin, peak insulin or peak C-peptide, between 17-OHP area under the curve (AUC) and insulin AUC or C-peptide AUC, and between percent increment in 17-OHP and insulin AUC or C-peptide AUC (P > 0.05).
  
  
  CONCLUSIONS
  Lack of a relationship between the 17-OHP response to the GnRH agonist buserelin and hyperinsulinism suggests that hyperinsulinism may not play a role in the dysregulation of the cytochrome P450c17 alpha enzyme seen in PCOS.
authors.affiliation: Department of Obstetrics and Gynecology, Erciyes University, Faculty of Medicine, Kayseri, Turkey.
authors.forename: Y
authors.initials: Y
authors.lastname: Sahin
authors.forename: D
authors.initials: D
authors.lastname: Ayata
authors.forename: F
authors.initials: F
authors.lastname: Keleştimur
mesh_terms: D019326:17-alpha-Hydroxyprogesterone / Q000097:blood*; D000293:Adolescent; D000328:Adult; D002064:Buserelin / Q000494:pharmacology*; D002096:C-Peptide / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005947:Glucose / Q000494:pharmacology; D005951:Glucose Tolerance Test; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D007328:Insulin / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D011388:Prolactin / Q000097:blood; D013254:Steroid 17-alpha-Hydroxylase / Q000502:physiology; D013739:Testosterone / Q000097:blood; D013997:Time Factors
chemical_list: D002096:C-Peptide; D007328:Insulin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D019326:17-alpha-Hydroxyprogesterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013254:Steroid 17-alpha-Hydroxylase; D005947:Glucose; D002064:Buserelin